(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of 135.44% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.89%.
Taysha Gene Therapies's revenue in 2026 is $9,773,000.On average, 15 Wall Street analysts forecast TSHA's revenue for 2026 to be $1,109,723,566, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $4,524,500,689. On average, 11 Wall Street analysts forecast TSHA's revenue for 2027 to be $14,741,541,419, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $34,911,909,124.
In 2028, TSHA is forecast to generate $39,042,850,070 in revenue, with the lowest revenue forecast at $26,294,387,114 and the highest revenue forecast at $57,063,289,956.